Pharmaceutical News

RSS

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013

Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.

24 May 2013

Researchers discover how drug prevents cancer progression

In collaboration with Daniel Zenklusen, also a University of Montreal biochemistry professor and lead author and doctoral candidate Vincent Messier, discovered that when cells are starved for nutrients TOR sends a signal to shut down production of a chemical message in the form of RNA to synthesize B cyclin ", Dr. Michnick explained.

24 May 2013

New, improved drugs can boost body's natural flu killer system

A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have shown recently that another, more promising, approach is to focus on improving drugs that boost the body's natural flu killer system.

24 May 2013

Senate immigration bill would ease restrictions on foreign health workers; Measure advances to increase scrutiny on compounding pharmacies

On Capitol Hill, several legislative efforts are moving forward on health issues. Among them is an effort by the Massachusetts delegation to keep bonus Medicare payments for the state's hospitals, while House Republicans are looking for another way to deal with a bill to fund high-risk insurance pools.

24 May 2013

Researchers recommend that bexarotene should not be tested on Alzheimer's patients

Approximately a year ago, the leading journal Science published an article about bexarotene as a potential Alzheimer's drug. A significant breakthrough and an important starting point for further Alzheimer's research.

24 May 2013

Drug addiction can be visualized in specific regions of brain that determine decision-making

New research shows that craving drugs such as nicotine can be visualized in specific regions of the brain that are implicated in determining the value of actions, in planning actions and in motivation.

24 May 2013

Groundbreaking anti-aging dietary supplement

Jeunesse Global, a network marketing company that dedicates its research to promoting healthy and youthful living, has produced the solution to one of the fundamental causes of cellular aging.

23 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

Omeros Corporation today announced that its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration.

23 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

New drug delivery system can help treat lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

23 May 2013

Study: Calcium supplements can help women live longer

Taking a calcium supplement of up to 1,000 mg per day can help women live longer, according to a study whose lead author was Lisa Langsetmo, a Ph.D. Research Associate at McGill University, and whose senior author was Prof. David Goltzman, Division of Endocrinology and Metabolism in the Department of Medicine of the Faculty of Medicine and researcher in the Musculoskeletal Disorders axis at the Research Institute of the McGill University Health Centre (RI-MUHC).

23 May 2013

Study sheds light on the phenomenon of general anesthesia

A study from the June issue of Anesthesiology found feedback from the front region of the brain is a crucial building block for consciousness and that its disruption is associated with unconsciousness when the anesthetics ketamine, propofol or sevoflurane are administered.

23 May 2013

Merck releases statement on FDA's Advisory Committee meeting about suvorexant

Merck, known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration about suvorexant, Merck's investigational medicine to treat insomnia.

23 May 2013

European, US NSTE-ACS guidelines recommend bivalirudin alone in patients undergoing PCI

Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.

23 May 2013

Research findings reveal promising new anti-addiction drug

Researchers at Johns Hopkins have unraveled the molecular foundations of cocaine's effects on the brain, and identified a compound that blocks cravings for the drug in cocaine-addicted mice.

23 May 2013

Scientists make important step forward in the quest to develop universal influenza vaccine

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets.

23 May 2013

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch platform.

22 May 2013

Antidepressant treatment results in lower rate of MSIMI

Among patients with stable coronary heart disease and mental stress-induced myocardial ischemia (MSIMI), 6 weeks of treatment with the antidepressant escitalopram, compared with placebo, resulted in a lower rate of MSIMI, according to a study in the May 22/29 issue of JAMA.

22 May 2013